GT200600107A - Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos - Google Patents
Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidosInfo
- Publication number
- GT200600107A GT200600107A GT200600107A GT200600107A GT200600107A GT 200600107 A GT200600107 A GT 200600107A GT 200600107 A GT200600107 A GT 200600107A GT 200600107 A GT200600107 A GT 200600107A GT 200600107 A GT200600107 A GT 200600107A
- Authority
- GT
- Guatemala
- Prior art keywords
- sulfonylaminofeniletil
- phenoxyacetamide
- substituted compounds
- compounds
- neuralgia
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA GENERAL I EN LA QUE R1,R2,R3,R4,R5, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR VR1 POR LO QUE SON DE UTILIDAD EN CUADROS NEUROPATÍAS, NEURALGÍA, MIGRAÑA ENTRE OTRAS DESCRITAS EN LA SOLICITUD.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66097805P | 2005-03-10 | 2005-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200600107A true GT200600107A (es) | 2006-12-26 |
Family
ID=36297248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200600107A GT200600107A (es) | 2005-03-10 | 2006-03-09 | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7566739B2 (es) |
| EP (1) | EP1858865B1 (es) |
| JP (1) | JP4906839B2 (es) |
| AR (1) | AR052938A1 (es) |
| AT (1) | ATE443056T1 (es) |
| CA (1) | CA2600409C (es) |
| DE (1) | DE602006009231D1 (es) |
| DO (1) | DOP2006000060A (es) |
| ES (1) | ES2331153T3 (es) |
| GT (1) | GT200600107A (es) |
| MX (1) | MX2007011105A (es) |
| NL (1) | NL1031335C2 (es) |
| PE (1) | PE20061163A1 (es) |
| TW (1) | TW200700398A (es) |
| UY (1) | UY29412A1 (es) |
| WO (1) | WO2006095263A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物 |
| WO2006101318A1 (en) * | 2005-03-19 | 2006-09-28 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| WO2007120012A1 (en) * | 2006-04-19 | 2007-10-25 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| AU2007277519B2 (en) | 2006-07-27 | 2011-12-22 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| WO2009096701A2 (en) | 2008-01-28 | 2009-08-06 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| KR102340754B1 (ko) | 2008-04-21 | 2021-12-16 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| US8691855B2 (en) | 2008-07-02 | 2014-04-08 | Amorepacific Corporation | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same |
| CA2731769C (en) | 2008-07-21 | 2013-09-10 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| US8835444B2 (en) | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
| WO2012009698A1 (en) | 2010-07-16 | 2012-01-19 | Abbott Laboratories | Phosphine ligands for catalytic reactions |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| EP3415504A1 (en) | 2010-07-16 | 2018-12-19 | AbbVie Ireland Unlimited Company | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| EP3478269A4 (en) | 2016-06-29 | 2020-04-08 | Otonomy, Inc. | OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES |
| US20200039922A1 (en) * | 2016-10-05 | 2020-02-06 | Afecta Pharmaceuticals, Inc. | High mobility group b1 protein inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810716A (en) | 1986-04-11 | 1989-03-07 | Warner-Lambert Company | Diarylalkanoids having activity as lipoxygenase inhibitors |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| RU2002110295A (ru) | 1999-09-17 | 2003-12-10 | Милленниум Фармасьютикалс, Инк. (Us) | Ингибиторы фактора Ха |
| BR0014076A (pt) | 1999-09-17 | 2002-10-15 | Millennium Pharm Inc | Benzamidas e inibidores correlatos do fator xa |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| AU2001245353A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| ES2266227T3 (es) * | 2000-08-21 | 2007-03-01 | Pacific Corporation | Nuevos compuestos de (tio)urea y composiciones farmaceuticas que los contienen. |
| CA2417507A1 (en) * | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| MXPA04003157A (es) | 2001-10-04 | 2006-04-27 | Novartis Ag | Compuestos organicos. |
| AU2003222648A1 (en) | 2002-05-13 | 2003-12-02 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| KR100556158B1 (ko) * | 2002-10-17 | 2006-03-06 | (주) 디지탈바이오텍 | 신규 엔-하이드록시 티오우레아, 우레아 및 아미드계화합물 및 이를 함유하는 약제학적 조성물 |
| KR100707123B1 (ko) * | 2003-07-02 | 2007-04-16 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물 |
| US20050085449A1 (en) | 2003-10-15 | 2005-04-21 | Dalton James T. | Haloacetamide and azide substituted compounds and methods of use thereof |
| WO2005040093A1 (ja) | 2003-10-24 | 2005-05-06 | Kissei Pharmaceutical Co., Ltd. | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| CN101087771A (zh) * | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n-磺酰基氨基苄基-2-苯氧基乙酰胺化合物 |
-
2006
- 2006-02-24 AT AT06710536T patent/ATE443056T1/de not_active IP Right Cessation
- 2006-02-24 DE DE602006009231T patent/DE602006009231D1/de active Active
- 2006-02-24 EP EP06710536A patent/EP1858865B1/en not_active Not-in-force
- 2006-02-24 JP JP2008500290A patent/JP4906839B2/ja not_active Expired - Fee Related
- 2006-02-24 MX MX2007011105A patent/MX2007011105A/es active IP Right Grant
- 2006-02-24 CA CA2600409A patent/CA2600409C/en not_active Expired - Fee Related
- 2006-02-24 WO PCT/IB2006/000539 patent/WO2006095263A1/en not_active Ceased
- 2006-02-24 ES ES06710536T patent/ES2331153T3/es active Active
- 2006-03-08 UY UY29412A patent/UY29412A1/es not_active Application Discontinuation
- 2006-03-08 PE PE2006000268A patent/PE20061163A1/es not_active Application Discontinuation
- 2006-03-08 AR ARP060100869A patent/AR052938A1/es unknown
- 2006-03-09 GT GT200600107A patent/GT200600107A/es unknown
- 2006-03-09 NL NL1031335A patent/NL1031335C2/nl not_active IP Right Cessation
- 2006-03-09 TW TW095108023A patent/TW200700398A/zh unknown
- 2006-03-09 DO DO2006000060A patent/DOP2006000060A/es unknown
- 2006-03-10 US US11/372,706 patent/US7566739B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TW200700398A (en) | 2007-01-01 |
| ES2331153T3 (es) | 2009-12-22 |
| MX2007011105A (es) | 2007-10-08 |
| PE20061163A1 (es) | 2006-10-27 |
| NL1031335C2 (nl) | 2007-01-23 |
| US20060205980A1 (en) | 2006-09-14 |
| EP1858865B1 (en) | 2009-09-16 |
| JP4906839B2 (ja) | 2012-03-28 |
| UY29412A1 (es) | 2006-10-31 |
| WO2006095263A8 (en) | 2007-11-08 |
| JP2008532994A (ja) | 2008-08-21 |
| AR052938A1 (es) | 2007-04-11 |
| EP1858865A1 (en) | 2007-11-28 |
| DE602006009231D1 (de) | 2009-10-29 |
| US7566739B2 (en) | 2009-07-28 |
| CA2600409C (en) | 2011-07-05 |
| NL1031335A1 (nl) | 2006-09-12 |
| DOP2006000060A (es) | 2006-09-30 |
| CA2600409A1 (en) | 2006-09-14 |
| WO2006095263A1 (en) | 2006-09-14 |
| ATE443056T1 (de) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200600107A (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos | |
| GT200500101A (es) | Compuestos de metil-aril o heteroaril-amida sustituida | |
| GT200400173A (es) | Compuestos de aril o heteroaril amida | |
| GT200300028A (es) | Derivados iii de dihidrobenzodiacepina-2-ona | |
| GT200400013A (es) | Compuestos de pirazolotriazina y usos de los mismos | |
| GT200600306A (es) | Inhibidores de glutamato agrecanasa | |
| GT200600030A (es) | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 | |
| GT200500226A (es) | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa | |
| GT200600356A (es) | Mezclas fungicidas que contienen anilidas sustituidas de acido 1-metilpirazol-4-ilcarboxilico. | |
| GT200500185A (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| GT200800103A (es) | 5-aril isoxazolinas para controlar plagas de invertebrados | |
| GT200600184A (es) | Derivados de purina | |
| GT200500286A (es) | Analogos de anilino-pirimidina | |
| GT200600205A (es) | Nuevos herbicidas | |
| GT200600197A (es) | Compuestos y composiciones como inhibidores de proteina quinasa | |
| GT200500183A (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| ECSP088623A (es) | Derivados de azepinoindol como agentes farmacéuticos | |
| GT200600329A (es) | Fungicidas carboxamidas | |
| GT200300258A (es) | Activadores de ppar | |
| NO20071476L (no) | Antidiuretiske midler. | |
| GT200500272A (es) | 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos | |
| GT200200269A (es) | Derivados de 7-amino-benzotiazol | |
| GT200600128A (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
| GT200600024A (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| GT200300045A (es) | Nuevos derivados de tiazol como antagonistas del receptor npy |